Pfizer, US ink $5.29B deal for possible COVID-19 treatment

pfizer us ink 5 29b deal for possible covid 19 treatment

Sumary of Pfizer, US ink $5.29B deal for possible COVID-19 treatment:

  • The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators authorize it.
  • The U.S. has already agreed to pay roughly $700 per course of Merck’s drug for about 1.7 million treatments.
  • -backed group to allow generic drugmakers to produce low-cost versions of the pill for certain countries.
  • Pfizer reported earlier this month that its pill cut hospitalizations and deaths by 89% among high-risk adults who had early symptoms of COVID-19. The company studied its pill in people who were unvaccinated and faced the worst risks from the virus due to age or health problems, such as obesity.
  • Pfizer wants the drug available for adults who have mild-to-moderate COVID-19 infections and are at risk of becoming seriously ill.
  • But all FDA-authorized COVID-19 treatments require an IV or injection given by a health professional at a hospital or clinic.

Want to know more click here go to source.

From -

Close

Site Language


Popular Posts

696

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close